Envista (NYSE:NVST) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Envista (NYSE:NVST) had its price target increased by Wells Fargo & Company from $20.00 to $21.00 in a report released on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential downside of 3.30% from the stock’s previous close.

A number of other research firms also recently weighed in on NVST. Morgan Stanley increased their price target on Envista from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Thursday. Piper Sandler increased their target price on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday. Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and boosted their target price for the stock from $16.00 to $23.00 in a research report on Thursday, October 31st. Leerink Partnrs upgraded shares of Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC restated a “hold” rating on shares of Envista in a report on Thursday. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Envista presently has a consensus rating of “Hold” and an average price target of $20.21.

Envista Trading Up 5.6 %

NVST stock traded up $1.15 during midday trading on Thursday, reaching $21.72. The stock had a trading volume of 1,579,702 shares, compared to its average volume of 2,031,756. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of -2.82, a PEG ratio of 1.82 and a beta of 1.34. Envista has a twelve month low of $15.15 and a twelve month high of $24.79. The company has a quick ratio of 1.77, a current ratio of 2.08 and a debt-to-equity ratio of 0.42. The business has a fifty day simple moving average of $19.97 and a two-hundred day simple moving average of $19.10.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. As a group, research analysts expect that Envista will post 0.72 EPS for the current fiscal year.

Institutional Trading of Envista

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Amalgamated Bank grew its position in Envista by 0.7% in the fourth quarter. Amalgamated Bank now owns 80,380 shares of the company’s stock valued at $1,551,000 after purchasing an additional 523 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Envista by 50.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares during the last quarter. Blue Trust Inc. raised its holdings in Envista by 69.7% during the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after acquiring an additional 804 shares in the last quarter. Finally, Huntington National Bank boosted its position in Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after purchasing an additional 949 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.